C4 Therapeutics (CCCC) Earnings Call Presentation

Cemsidomide (IKZF1/3 Degrader) in Multiple Myeloma (MM) & Non-Hodgkin's Lymphoma (NHL) - Cemsidomide dose escalation is complete with 100 µg QD dose level declared safe, and patients are enrolling in the expansion cohort at this dose level[28] - In MM, at the 100 µg dose level, one patient achieved an MRD negative CR, and eight patients (80%) received prior CAR-T or T-cell engager therapy[39] - In NHL, Cemsidomide was well-tolerated with manageable incidents of on-target neutropenia[53] - In PTCL subtypes, the ORR is 44%[56] - Cemsidomide has the potential to achieve peak annual revenues of ~$1 billion as a 5L+ treatment option +dex and over $6 billion if labels in combination with a BCMA bispecific and in combination with dex + an anti-CD38 are achieved[48] CFT8919 (EGFR L858R Degrader) in Non-Small Cell Lung Cancer (NSCLC) - CFT8919 is a potent, oral, allosteric, mutant-selective degrader of EGFR L858R with potential to improve outcomes for NSCLC patients[66] - 2024 Annual Incidence of EGFR L858R Mutated NSCLC: U S: ~17,000, China: ~189,000, EU4 + UK: ~13,000[85] Portfolio & Milestones - Multiple 2025 milestones are expected across the portfolio, including data presentations and clinical trial advancements[18, 86] - In May 2025, C4T announced CFT1946 will not advance beyond Phase 1 and that the company will seek partnership for the BRAF program[17]